Printer Friendly

U.S. DRUG TESTING INC. ANNOUNCES SECOND QUARTER LOSSES

 RANCHO CUCAMONGA, Calif., Nov. 16 /PRNewswire/ -- Gary S. Wolff, chief financial officer of U.S. Drug Testing Inc. announced today its losses for the six months and three months ended Sept. 30, 1993.
 Six months Three months
 Ended Sept. 30, 1993
 Net revenues 0 0
 Loss from operations (841,169) (436,995)
 Loss per common share(a) ($.24) ($.12)
 (a) Based upon 3,500,000 outstanding common shares owned by U.S. Alcohol Testing before completion of the company's initial public offering.
 On Oct. 5, 1993, U.S. Drug Testing announced that the Securities and Exchange Commission had declared its initial public offering effective and that 1,721,900 common shares (including overallotment option of 221,900 shares exercised by the underwriter) or 33 percent of the outstanding common shares, are currently trading.
 U.S. Drug Testing Inc. is a 67 percent owned subsidiary of U.S. Alcohol Testing of America Inc. (AMEX: AAA) and is engaged in the research and development of devices which detect drugs of abuse from urine and saliva samples.
 -0- 11/16/93
 /CONTACT: Gary S. Wolff of U.S. Drug Testing, 909-466-8378/


CO: U.S. Drug Testing Inc. ST: California IN: HEA SU: ERN

NY-LM -- LA005 -- 4863 11/16/93 08:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1993
Words:209
Previous Article:HONDO ANNOUNCES NEW CHIEF EXECUTIVE OFFICER
Next Article:INTERNATIONAL VIDEO NETWORK PRESENTS A ONE-TIME ONLY VIDEO GIFT PACK OFFER FOR THE HOLIDAYS 'JESUS AND HIS TIMES'
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters